PMID- 32370462
OWN - NLM
STAT- MEDLINE
DCOM- 20200812
LR  - 20200812
IS  - 0578-1426 (Print)
IS  - 0578-1426 (Linking)
VI  - 59
IP  - 5
DP  - 2020 May 1
TI  - [The efficacy and safety of daratumumab in relapsed and refractory multiple 
      myeloma].
PG  - 347-352
LID - 10.3760/cma.j.cn112138-20191217-00821 [doi]
AB  - Objective: To investigate the efficacy and safety of daratumumab in relapsed and 
      refractory multiple myeloma (RRMM). Methods: The efficacy and adverse events 
      (AEs) of daratumumab based regimens were retrospectively analyzed in 37 patients 
      with RRMM from Peking University People's Hospital, Beijing Hospital and Fu Xing 
      Hospital affiliated to Capital Medical University in China. The deadline for 
      inclusion was December, 2019. Results: Among the 37 patients, 35 patients were 
      available for response evaluation. The overall response rate (ORR) was 68.6%, 
      which was better in patients receiving 16 mg/kg daratumumab than in those with 
      fixed doses of 800 mg daratumumab [ORR: 78.3%(18/23) vs. 40.0%(4/10)]. The 
      percentage of infusion related reactions of daratumumab was 27.0%(10/37). The 
      most common hematological AEs were lymphocytopenia and thrombocytopenia, with the 
      incidences of grade 3 or more severe 59.5%(22/37) and 43.2%(16/37) respectively. 
      Pulmonary infections(37.8%, 14/37) were the most common non-hematological AEs. 
      One patient with positive hepatitis B surface antigen (HBsAg) and two patients 
      dependent on dialysis were safely treated with daratumumab. Conclusion: 
      Daratumumab is highly effective in relapsed and refractory multiple myeloma. 
      Adverse reactions are mild and well tolerable.
FAU - Jia, Y J
AU  - Jia YJ
AD  - Department of Hematology, Peking University People's Hospital, Peking University 
      Institute of Hematology, National Clinical Research Center for Hematologic 
      Disease, Beijing 100044, China; Department of Hematology, The First Hospital of 
      Fangshan District, Beijing 102400, China.
FAU - Liu, H
AU  - Liu H
AD  - Department of Hematology, Beijing Hospital, Beijing 100730, China.
FAU - Wang, L R
AU  - Wang LR
AD  - Department of Hematology, Fu Xing Hospital, Capital Medical University, Beijing 
      100045, China.
FAU - Wang, T
AU  - Wang T
AD  - Department of Hematology, Beijing Hospital, Beijing 100730, China.
FAU - Feng, R
AU  - Feng R
AD  - Department of Hematology, Beijing Hospital, Beijing 100730, China.
FAU - Chen, Y J
AU  - Chen YJ
AD  - Department of Hematology, Fu Xing Hospital, Capital Medical University, Beijing 
      100045, China.
FAU - Wang, M
AU  - Wang M
AD  - Department of Hematology, Fu Xing Hospital, Capital Medical University, Beijing 
      100045, China.
FAU - Guo, H X
AU  - Guo HX
AD  - Department of Hematology, Fu Xing Hospital, Capital Medical University, Beijing 
      100045, China.
FAU - Wen, L
AU  - Wen L
AD  - Department of Hematology, Peking University People's Hospital, Peking University 
      Institute of Hematology, National Clinical Research Center for Hematologic 
      Disease, Beijing 100044, China.
FAU - Duan, W B
AU  - Duan WB
AD  - Department of Hematology, Peking University People's Hospital, Peking University 
      Institute of Hematology, National Clinical Research Center for Hematologic 
      Disease, Beijing 100044, China.
FAU - Yang, Y Z
AU  - Yang YZ
AD  - Department of Hematology, Beijing Hospital, Beijing 100730, China.
FAU - Wang, F R
AU  - Wang FR
AD  - Department of Hematology, Peking University People's Hospital, Peking University 
      Institute of Hematology, National Clinical Research Center for Hematologic 
      Disease, Beijing 100044, China.
FAU - Chen, Y Y
AU  - Chen YY
AD  - Department of Hematology, Peking University People's Hospital, Peking University 
      Institute of Hematology, National Clinical Research Center for Hematologic 
      Disease, Beijing 100044, China.
FAU - Huang, X J
AU  - Huang XJ
AD  - Department of Hematology, Peking University People's Hospital, Peking University 
      Institute of Hematology, National Clinical Research Center for Hematologic 
      Disease, Beijing 100044, China.
FAU - Lu, J
AU  - Lu J
AD  - Department of Hematology, Peking University People's Hospital, Peking University 
      Institute of Hematology, National Clinical Research Center for Hematologic 
      Disease, Beijing 100044, China; Center for Collaborative Innovation in 
      Hematology, Suzhou 215006, China.
LA  - chi
PT  - Journal Article
PL  - China
TA  - Zhonghua Nei Ke Za Zhi
JT  - Zhonghua nei ke za zhi
JID - 16210490R
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antineoplastic Agents)
RN  - 4Z63YK6E0E (daratumumab)
SB  - IM
MH  - Antibodies, Monoclonal/adverse effects/*therapeutic use
MH  - Antineoplastic Agents/adverse effects/*therapeutic use
MH  - China
MH  - Humans
MH  - Multiple Myeloma/*therapy
MH  - Retrospective Studies
OTO - NOTNLM
OT  - Daratumumab
OT  - Multiple myeloma
OT  - Refractory
OT  - Relapsed
EDAT- 2020/05/07 06:00
MHDA- 2020/08/13 06:00
CRDT- 2020/05/07 06:00
PHST- 2020/05/07 06:00 [entrez]
PHST- 2020/05/07 06:00 [pubmed]
PHST- 2020/08/13 06:00 [medline]
AID - 10.3760/cma.j.cn112138-20191217-00821 [doi]
PST - ppublish
SO  - Zhonghua Nei Ke Za Zhi. 2020 May 1;59(5):347-352. doi: 
      10.3760/cma.j.cn112138-20191217-00821.